Long-term effects of dapagliflozin, a SGLT2 inhibitor, on glucose metabolism in patients with type 2 diabetes mellitus

Long-term effects of dapagliflozin, a SGLT2 inhibitor, on glucose metabolism in patients with type 2 diabetes mellitus - Long-term effects of dapagliflozinon glucose metabolism in patients with diabetes mellitus

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000026042

Enrollment

300

Registered

2017-02-08

Start date

2017-02-08

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

type 2 diabetes mellitus

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: HbA1c > 7.0% Patients treated with dapagliflozin for more than 24 week

Exclusion criteria

Exclusion criteria: Repeated urinary tract infection HbA1c < 7.0% BMI < 22

Design outcomes

Primary

Measure	Time frame
fasting blood glucose, HbA1c, urinary sugar	—

Countries

Japan

Contacts

Public ContactTakumi Kawaguchi

Kurume University School of Medicine Division of Gastroenteorlogy, Department of Medicine

takumi@med.kurume-u.ac.jp0942317561

Outcome results